$COCP This appointment is not just filler. James Sapirstein’s biggest accomplishment was as CEO of Tobira Therapeutics (cofounded the company). In 2016, Allergan acquired Tobira for $1.7 billion in an all-cash deal, which represented roughly a 43x return for investors at the time
$COCP Cocrystal just appointed James Sapirstein as new CEO.
Sapirstein brings extensive Antiviral development and commercialization experience (former CEO of Contravir and Tobira, senior roles at Gilead and BMS). Sam Lee moves to President & Chief Scientific Officer. Jim Martin stays as CFO.
Solid addition to the team as the Norovirus program advances.
https://t.co/zdS0qIf6aj
Recent wastewater surveillance reveals an upward trend to “high” levels of norovirus across much of the country, with rates currently rising in the Northeast. https://t.co/NrigJpADZJ
$COCP New 13F May 8, 2026
Vanguard brand new position
Vanguard Capital: 239,971 sh
Vanguard Trust: 24,016 sh
This is the start of first meaningful new institutional buying seen in years. It’s still a small position for but in $20M mc with a tiny real float, 264k sh is noticeable
@ms101phd $COCP this is similar escalation phase map from $GME playbook in 2021 from the GME playbook fees spike hard right before the forced covering starts feeding on itself. If co announced barda boom
@ms101phd@hVIVO_UK $COCP @hVIVO_UK 42344 flu challenge you ran that was a total mess (low placebo shedding = inconclusive, program deprioritized). Selective PR game strong. Cherry-picking wins only? Time the CRO is exposed and if viral bad look @CocrystalPharma
A norovirus outbreak sickened more than 150 passengers and crew aboard a Princess cruise ship as it sailed through the Caribbean last week, the U.S. Centers for Disease Control and Prevention announced. https://t.co/kDnr5i5EVg
$COCP Form 4, New insider buy billionaire Phillip Frost 20K shares. This brings his total open market purchases since November 2025 to 229,000 shares. His cumulative beneficial ownership (indirect through Frost Gamma Investments Trust) after this transaction is 1,908,551 shares
On the latest WTR Healthcare Happenings Podcast, Tim Gerdeman and Robert Sassoon speak with James J. Martin, CPA, Co-CEO and CFO of Cocrystal Pharma, Inc. (NASDAQ: $COCP), about the company’s clinical-stage antiviral opportunity.
Listen to the full episode to learn more about CDI-988, upcoming catalysts, and Cocrystal’s broader antiviral strategy.
Podcast Platforms: https://t.co/4Xh9WeH21g
Website: https://t.co/QFoIN5YA3K
$COCP #CocrystalPharma #Norovirus #AntiviralTherapies #Biotech #ClinicalTrials #HealthcareInnovation #InfectiousDisease #DrugDiscovery #SmallCaps #HealthcareHappenings #WaterTowerResearch @CocrystalPharma
$COCP 2026: Derisking/re-rating event of the century. Catalysts stack: FDA Fast Track, enrollment start, BARDA/DoD funding, mid-year data. Fred Hassan (GOAT) running it w/ largest % stake ever. Frost loading heavy at lows. Blue-ocean norovirus monopoly + flu BARDA bonus = blockbuster asymmetry. The story is hiding in plain sight.